Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis.

Szczegóły
Abstrakt

Tytuł:: Diagnostic performance of neuromelanin-sensitive magnetic resonance imaging for patients with Parkinson's disease and factor analysis for its heterogeneity: a systematic review and meta-analysis.
Autorzy:: Cho SJ; Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea.
Bae YJ; Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea. .
Kim JM; Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea.
Kim D; Department of Radiology, Busan Paik Hospital, Inje University College of Medicine, 75, Bokji-ro, Busanjin-gu, Busan, 47392, Republic of Korea.
Baik SH; Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea.
Sunwoo L; Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea.
Choi BS; Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea.
Kim JH; Department of Radiology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 82, Gumi-ro 173beon-gil, Bundang-gu, Seongnam, Gyeonggi, 13620, Republic of Korea.
Źródło:: European radiology [Eur Radiol] 2021 Mar; Vol. 31 (3), pp. 1268-1280. Date of Electronic Publication: 2020 Sep 04.
Typ publikacji:: Journal Article; Meta-Analysis; Systematic Review
Język:: English
Imprint Name(s):: Original Publication: Berlin : Springer International, c1991-
MeSH Terms:: Parkinson Disease*/diagnostic imaging
Factor Analysis, Statistical ; Humans ; Magnetic Resonance Imaging ; Melanins ; Substantia Nigra
References:: Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL (2005) Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson’s disease. Prog Neurobiol 75:109–124. (PMID: 15784302)
Sulzer D, Zecca L (2000) Intraneuronal dopamine-quinone synthesis: a review. Neurotox Res 1:181–195. (PMID: 12835101)
Mann DM, Yates PO (1983) Pathological basis for neurotransmitter changes in Parkinson’s disease. Neuropathol Appl Neurobiol 9:3–19. (PMID: 6133229)
Nakamura K, Sugaya K (2014) Neuromelanin-sensitive magnetic resonance imaging: a promising technique for depicting tissue characteristics containing neuromelanin. Neural Regen Res 9:759–760. (PMID: 252068854146273)
Sasaki M, Shibata E, Tohyama K et al (2006) Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson’s disease. Neuroreport 17:1215–1218. (PMID: 16837857)
Wang X, Zhang Y, Zhu C et al (2019) The diagnostic value of SNpc using NM-MRI in Parkinson’s disease: meta-analysis. Neurol Sci. https://doi.org/10.1007/s10072-019-04014-y.
Castellanos G, Fernandez-Seara MA, Lorenzo-Betancor O et al (2015) Automated neuromelanin imaging as a diagnostic biomarker for Parkinson’s disease. Mov Disord 30:945–952. (PMID: 25772492)
Fabbri M, Reimao S, Carvalho M et al (2017) Substantia nigra neuromelanin as an imaging biomarker of disease progression in Parkinson’s disease. J Parkinsons Dis 7:491–501. (PMID: 28671143)
Isaias IU, Trujillo P, Summers P et al (2016) Neuromelanin imaging and dopaminergic loss in Parkinson’s disease. Front Aging Neurosci 8:196. (PMID: 275978254992725)
Kawaguchi H, Shimada H, Kodaka F et al (2016) Principal component analysis of multimodal neuromelanin MRI and dopamine transporter PET data provides a specific metric for the nigral dopaminergic neuronal density. PLoS One 11:e0151191. (PMID: 269546904783074)
Le Berre A, Kamagata K, Otsuka Y et al (2019) Convolutional neural network-based segmentation can help in assessing the substantia nigra in neuromelanin MRI. Neuroradiology. https://doi.org/10.1007/s00234-019-02279-w.
Ogisu K, Kudo K, Sasaki M et al (2013) 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson’s disease. Neuroradiology 55:719–724. (PMID: 23525598)
Ohtsuka C, Sasaki M, Konno K et al (2013) Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson’s disease using neuromelanin-sensitive MR imaging. Neurosci Lett 541:93–98. (PMID: 23428505)
Prasad S, Stezin A, Lenka A et al (2018) Three-dimensional neuromelanin-sensitive magnetic resonance imaging of the substantia nigra in Parkinson’s disease. Eur J Neurol 25:680–686. (PMID: 29341412)
Pyatigorskaya N, Magnin B, Mongin M et al (2018) Comparative study of MRI biomarkers in the substantia nigra to discriminate idiopathic Parkinson disease. AJNR Am J Neuroradiol 39:1460–1467. (PMID: 299548167410545)
Schwarz ST, Xing Y, Tomar P, Bajaj N, Auer DP (2017) In vivo assessment of brainstem depigmentation in Parkinson disease: potential as a severity marker for multicenter studies. Radiology 283:789–798. (PMID: 27820685)
Takahashi H, Watanabe Y, Tanaka H et al (2018) Comprehensive MRI quantification of the substantia nigra pars compacta in Parkinson’s disease. Eur J Radiol 109:48–56. (PMID: 30527311)
Zupan G, Suput D, Pirtosek Z, Vovk A (2019) Semi-automatic signature-based segmentation method for quantification of neuromelanin in substantia nigra. Brain Sci:9.
Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65–W94. (PMID: 19622512)
Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536. (PMID: 22007046)
Suh CH, Park SH (2016) Successful publication of systematic review and meta-analysis of studies evaluating diagnostic test accuracy. Korean J Radiol 17:5–6. (PMID: 267982114720811)
Kim KW, Lee J, Choi SH, Huh J, Park SH (2015) Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-part I. general guidance and tips. Korean J Radiol 16:1175–1187. (PMID: 265761064644738)
Lee J, Kim KW, Choi SH, Huh J, Park SH (2015) Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers-part II. Statistical methods of meta-analysis. Korean J Radiol 16:1188–1196. (PMID: 265761074644739)
Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH (2005) Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 58:982–990. (PMID: 16168343)
Rutter CM, Gatsonis CA (2001) A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Stat Med 20:2865–2884. (PMID: 11568945)
Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58:882–893. (PMID: 16085191)
Hoaglin DC (2016) Misunderstandings about Q and ‘Cochran's Q test’ in meta-analysis. Stat Med 35:485–495. (PMID: 26303773)
Deville WL, Buntinx F, Bouter LM et al (2002) Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2:9. (PMID: 12097142117243)
Cassidy CM, Zucca FA, Girgis RR et al (2019) Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Proc Natl Acad Sci U S A 116:5108–5117. (PMID: 307961876421437)
Kashihara K, Shinya T, Higaki F (2011) Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson’s disease. J Clin Neurosci 18:1093–1096. (PMID: 21719292)
Kuya K, Ogawa T, Shinohara Y et al (2018) Evaluation of Parkinson’s disease by neuromelanin-sensitive magnetic resonance imaging and (123)I-FP-CIT SPECT. Acta Radiol 59:593–598. (PMID: 28743197)
Kuya K, Shinohara Y, Miyoshi F, Fujii S, Tanabe Y, Ogawa T (2016) Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism. Neuroradiology 58:351–356. (PMID: 26779912)
Langley J, Huddleston DE, Sedlacik J, Boelmans K, Hu XP (2017) Parkinson’s disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta. Mov Disord 32:441–449. (PMID: 28004859)
Matsuura K, Maeda M, Yata K et al (2013) Neuromelanin magnetic resonance imaging in Parkinson’s disease and multiple system atrophy. Eur Neurol 70:70–77. (PMID: 23796701)
Moon WJ, Park JY, Yun WS et al (2016) A comparison of substantia nigra T1 hyperintensity in Parkinson’s disease dementia, Alzheimer’s disease and age-matched controls: volumetric analysis of neuromelanin imaging. Korean J Radiol 17:633–640. (PMID: 275879515007389)
Hatano T, Okuzumi A, Kamagata K et al (2017) Neuromelanin MRI is useful for monitoring motor complications in Parkinson’s and PARK2 disease. J Neural Transm (Vienna) 124:407–415.
Matsusue E, Fujihara Y, Tanaka K et al (2019) The utility of the combined use of (123)I-FP-CIT SPECT and neuromelanin MRI in differentiating Parkinson’s disease from other parkinsonian syndromes. Acta Radiol 60:230–238. (PMID: 29804474)
Ohtsuka C, Sasaki M, Konno K et al (2014) Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 20:755–760. (PMID: 24768616)
Shinde S, Prasad S, Saboo Y et al (2019) Predictive markers for Parkinson’s disease using deep neural nets on neuromelanin sensitive MRI. Neuroimage Clin 22:101748. (PMID: 308707336417260)
Wang J, Huang Z, Li Y et al (2019) Neuromelanin-sensitive MRI of the substantia nigra: an imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson’s disease. Parkinsonism Relat Disord 58:3–8. (PMID: 30037690)
Xiang Y, Gong T, Wu J et al (2017) Subtypes evaluation of motor dysfunction in Parkinson’s disease using neuromelanin-sensitive magnetic resonance imaging. Neurosci Lett 638:145–150. (PMID: 27993708)
Reimao S, Pita Lobo P, Neutel D et al (2015) Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson’s disease patients. Eur J Neurol 22:540–546. (PMID: 25534480)
Reimao S, Pita Lobo P, Neutel D et al (2015) Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson’s disease. Mov Disord 30:953–959. (PMID: 25758364)
Reimao S, Pita Lobo P, Neutel D et al (2015) Quantitative analysis versus visual assessment of neuromelanin MR imaging for the diagnosis of Parkinson’s disease. J Parkinsons Dis 5:561–567. (PMID: 26406136)
Takahashi H, Watanabe Y, Tanaka H et al (2018) Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson’s disease. Br J Radiol 91:20180037. (PMID: 294985406223299)
Taniguchi D, Hatano T, Kamagata K et al (2018) Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson’s disease. Mov Disord 33:1488–1492. (PMID: 29756366)
Jin L, Wang J, Wang C et al (2019) Combined visualization of nigrosome-1 and neuromelanin in the substantia nigra using 3T MRI for the differential diagnosis of essential tremor and de novo Parkinson’s disease. Front Neurol 10:100. (PMID: 308091896379476)
Sommerauer M, Fedorova TD, Hansen AK et al (2018) Evaluation of the noradrenergic system in Parkinson’s disease: an 11C-MeNER PET and neuromelanin MRI study. Brain 141:496–504. (PMID: 29272343)
Tanaka M, Aihara Y, Ikeda S, Aihara Y (2011) Neuromelanin-related contrast in the substantia nigra semiquantitatively evaluated by magnetic resonance imaging at 3T: comparison between normal aging and Parkinson disease. Rinsho Shinkeigaku 51:14–20. (PMID: 21387694)
Takahashi H, Watanabe Y, Tanaka H et al (2019) Quantifying the severity of Parkinson disease by use of dopaminergic neuroimaging. AJR Am J Roentgenol. https://doi.org/10.2214/ajr.18.20655:1-6.
Ehrminger M, Latimier A, Pyatigorskaya N et al (2016) The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain 139:1180–1188. (PMID: 26920675)
García-Lorenzo D, Longo-Dos Santos C, Ewenczyk C et al (2013) The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson's disease. Brain 136:2120–2129. (PMID: 238017363692035)
Ogura A, Maeda F, Miyai A, Kikumoto R (2005) Effects of slice thickness and matrix size on MRI for signal detection. Nihon Hoshasen Gijutsu Gakkai Zasshi 61:1140–1143. (PMID: 16132032)
Grant Information:: MSIT; No. 2019R1F1A1063771 National Research Foundation of Korea; Grant No. 09-2019-003 SNUBH Research Fund
Contributed Indexing:: Keywords: Magnetic resonance imaging; Neuromelanin; Parkinson disease
Substance Nomenclature:: 0 (Melanins)
0 (neuromelanin)
Entry Date(s):: Date Created: 20200905 Date Completed: 20210414 Latest Revision: 20210414
Update Code:: 20240104
DOI:: 10.1007/s00330-020-07240-7
PMID:: 32886201
: Czasopismo naukowe

Full Text Finder

Objective: To determine the diagnostic performance of neuromelanin-sensitive magnetic resonance imaging discriminating between patients with Parkinson's disease and normal healthy controls and to identify factors causing heterogeneity influencing the diagnostic performance.
Methods: A systematic literature search in the Ovid-MEDLINE and EMBASE databases was performed for studies reporting the relevant topic before February 17, 2020. The pooled sensitivity and specificity values with their 95% confidence intervals were calculated using bivariate random-effects modeling. Subgroup and meta-regression analyses were also performed to determine factors influencing heterogeneity.
Results: Twelve articles including 403 patients with Parkinson's disease and 298 control participants were included in this systematic review and meta-analysis. Neuromelanin-sensitive magnetic resonance imaging showed a pooled sensitivity of 89% (95% confidence interval, 86-92%) and a pooled specificity of 83% (95% confidence interval, 76-88%). In the subgroup and meta-regression analysis, a disease duration longer than 5 and 10 years, comparisons using measured volumes instead of signal intensities, a slice thickness in terms of magnetic resonance imaging parameters of more than 2 mm, and semi-/automated segmentation methods instead of manual segmentation improved the diagnostic performance.
Conclusion: Neuromelanin-sensitive magnetic resonance imaging had a favorable diagnostic performance in discriminating patients with Parkinson's disease from healthy controls. To improve diagnostic accuracy, further investigations directly comparing these heterogeneity-affecting factors and optimizing these parameters are necessary.
Key Points: • Neuromelanin-sensitive MRI favorably discriminates patients with Parkinson's disease from healthy controls. • Disease duration, parameters used for comparison, magnetic resonance imaging slice thickness, and segmentation methods affected heterogeneity across the studies.

Informacja